FDA’s Drug Naming Pilot Moves Forward, But Industry May Need Sweeter Rewards
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms lack explicit incentives to participate in the proposed self-evaluation, which will be discussed at a public meeting June 5-6.
You may also be interested in...
Trade Name “Bank” Proposed For Neutral/Extreme Controls In FDA Pilot
FDA’s proposal includes limited number of control names.
Trade Name “Bank” Proposed For Neutral/Extreme Controls In FDA Pilot
FDA’s proposal includes limited number of control names.
FDA’s Trade Name Review Questioned At Public Meeting
Industry wonders whether its pilot submissions hold weight against agency evaluations.